Deborah DeRyckere

List of Publications by Year
in descending order

45 papers	1,956 citations	304743 22 h-index	345221 36 g-index
48 all docs	48 docs citations	48 times ranked	2787 citing authors

#	Article	IF	Citations
1	Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia. Nature Communications, 2022, 13, 1157.	12.8	12
2	MERTK activation drives osimertinib resistance in EGFR-mutant nonâ€“small cell lung cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	12
3	Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia. , 2022, 10, e004774.		0
4	Abstract 1109: A novel strategy to cope with osimertinib resistance in non-small cell lung cancer by treatment with a PIM kinase inhibitor in combination with a MERTK-selective kinase inhibitor. , 2021, , .		1
5	UNC5293, a potent, orally available and highly MERTK-selective inhibitor. European Journal of Medicinal Chemistry, 2021, 220, 113534.	5.5	4
6	Therapeutic Targeting of Mertk and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia. Blood, 2021, 138, 1184-1184.	1.4	3
7	Analysis of Single Cell Transcriptomics in Paired Pediatric T-ALL Samples Collected at Diagnosis and Following End of Induction Therapy Reveals an MRD-Associated Stem Cell Signature. Blood, 2021, 138, 1311-1311.	1.4	1
8	Single Cell RNA Sequencing Driven Characterization of Rare B/Myeloid and T/Myeloid Mixed Phenotype Acute Leukemia. Blood, 2021, 138, 3455-3455.	1.4	0
9	Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer. Cancers, 2021, 13, 5639.	3.7	13
10	MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. , 2020, 213, 107577.		43
11	Risk-associated alterations in marrow T cells in pediatric leukemia. JCI Insight, 2020, 5, .	5.0	23
12	Abstract 1882: MERTK drives residual tumor growth inEGFR-mutated non-small cell lung cancer cells treated with osimertinib. , 2020, , .		1
13	Characterization of T-ALL-Specific Heterogenous Blast Populations Using High Resolution Single Cell Profiling. Blood, 2020, 136, 11-12.	1.4	1
14	Single Cell Transcriptomics Revealed AML and Non-AML Cell Clusters Relevant to Relapse and Remission in Pediatric AML. Blood, 2020, 136, 24-25.	1.4	5
15	Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies. , 2019, , 61-85.		1
16	Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology. Journal of the American Chemical Society, 2019, 141, 15700-15709.	13.7	12
17	MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight, 2018, 3, .	5.0	51
18	The Emerging Role of TYRO3 as a Therapeutic Target in Cancer. Cancers, 2018, 10, 474.	3.7	60

#	Article	IF	Citations
19	Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. Journal of Medicinal Chemistry, 2018, 61, 10242-10254.	6.4	20
20	MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Nonâ€“small Cell Lung Cancers Expressing Wild-type EGFR Family Members. Clinical Cancer Research, 2018, 24, 6523-6535.	7.0	25
21	MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Molecular Cancer Therapeutics, 2018, 17, 2297-2308.	4.1	36
22	Discovery of Macrocyclic Pyrimidines as MerTKâ€Specific Inhibitors. ChemMedChem, 2017, 12, 207-213.	3.2	25
23	UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clinical Cancer Research, 2017, 23, 1481-1492.	7.0	58
24	The Current State of FLT3 Inhibition in Acute Myeloid Leukemia â€“ Pitfalls and Promises. Journal of Cell Signaling, 2017, 02, .	0.3	3
25	Targeting the TAM Receptors in Leukemia. Cancers, 2016, 8, 101.	3.7	32
26	Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 1044-1049.	2.8	19
27	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight, 2016, 1, e85630.	5.0	55
28	Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations. Clinical Cancer Research, 2015, 21, 1360-1372.	7.0	58
29	Small Molecule Inhibition of MERTK Is Efficacious in Nonâ€“Small Cell Lung Cancer Models Independent of Driver Oncogene Status. Molecular Cancer Therapeutics, 2015, 14, 2014-2022.	4.1	45
30	Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget, 2015, 6, 6722-6736.	1.8	38
31	The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer. Nature Reviews Cancer, 2014, 14, 769-785.	28.4	541
32	UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor. Journal of Medicinal Chemistry, 2014, 57, 7031-7041.	6.4	125
33	Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget, 2014, 5, 10434-10445.	1.8	30
34	Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission. Journal of Hematology and Oncology, 2013, 6, 10.	17.0	24
35	Mer receptor tyrosine kinase is a therapeutic target in preâ€“B-cell acute lymphoblastic leukemia. Blood, 2013, 122, 1599-1609.	1.4	62
36	UNC1062, a new and potent Mer inhibitor. European Journal of Medicinal Chemistry, 2013, 65, 83-93.	5.5	58

#	Article	IF	Citations
37	UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo. Molecular Cancer Therapeutics, 2013, 12, 2367-2377.	4.1	53
38	Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia. Journal of Visualized Experiments, 2013, , e50720.	0.3	4
39	MERTK receptor tyrosine kinase is a therapeutic target in melanoma. Journal of Clinical Investigation, 2013, 123, 2257-2267.	8.2	124
40	MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. Journal of Clinical Investigation, 2013, 123, 3231-3242.	8.2	153
41	Abstract A110: Inhibition of MerTK in tumor infiltrating leukocytes decreases tumor growth in a mouse model of breast cancer. , 2013, , .		0
42	Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. ACS Medicinal Chemistry Letters, 2012, 3, 129-134.	2.8	67
43	E2F1 and E2F2 Are Differentially Required for Homeostasis-Driven and Antigen-Induced T Cell Proliferation In Vivo. Journal of Immunology, 2005, 175, 647-655.	0.8	15
44	Characterization of Transcriptional Regulation During Negative Selection In Vivo. Journal of Immunology, 2003, 171, 802-811.	0.8	33
45	Identification and characterization of transcription factor target genes using gene-targeted mice. Methods, 2002, 26, 57-75.	3.8	10